Phil McEwan

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 10

Top Venues

Diabetes, obesity & metabolism

PharmacoEconomics

ClinicoEconomics and outcomes research : CEOR

Advances in therapy

Cardiff University (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

Cardiff University Sep 30 1997 - Aug 27 2000

United Kingdom

PHD :: Mathematics

Publications

Ricardo Correa-Rotter, David C Wheeler, Phil McEwan
The Broader Effects of Delayed Progression to End-Stage Kidney Disease: Delaying the Inevitable or a Meaningful Change? Advances in therapy (2024)
Phil McEwan, Volker Foos, Becky Martin, Jieling Chen, Lyndon Marc Evans
Estimating the value of SGLT2 inhibitors within the context of contemporary guidelines and totality of evidence. Diabetes, obesity & metabolism (2023)
Phil McEwan, Angharad R Morgan, Rebecca Boyce, Klas Bergenheim, Ingrid A M Gause-Nilsson, Deepak L Bhatt, Lawrence Alan Leiter, Peter A Johansson, Lawrence A Leiter, Avivit Cahn, John P H Wilding
The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial. Diabetes, obesity & metabolism 23 (4) (2021)
Sandra Lopes, Pierre Johansen, Mark Lamotte, Phil McEwan, Anamaria-Vera Olivieri, Volker Foos
External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions. PharmacoEconomics 38 (10) (2021)
Eirini Palaka, Susan Grandy, Heleen van Haalen, Phil McEwan, Oliver Darlington
The Impact of CKD Anaemia on Patients: Incidence, Risk Factors, and Clinical Outcomes-A Systematic Literature Review. International journal of nephrology 2020 (2020)
Sandra Lopes, Pierre Johansen, Mark Lamotte, Phil McEwan, Anamaria-Vera Olivieri, Volker Foos
Authors' reply to Comment on "External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions". PharmacoEconomics 39 (1) (2020)
Eddie J Gibson, Najida Begum, Ian Koblbauer, George Dranitsaris, Danny Liew, Phil McEwan, Yong Yuan, Ariadna Juarez-Garcia, David Tyas, Clive Pritchard
Economic Evaluation of Single versus Combination Immuno-Oncology Therapies: Application of a Novel Modelling Approach in Metastatic Melanoma. ClinicoEconomics and outcomes research : CEOR 12 (2020)
Phil McEwan, Hayley Bennett, Kamlesh Khunti, John P H Wilding, Christopher Edmonds, Marcus Thuresson, Eric T Wittbrodt, Peter Fenici, Mikhail Naum Kosiborod
Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real-world evidence. Diabetes, obesity & metabolism 22 (12) (2020)
Jason Gordon, Lee Beresford-Hulme, Hayley Bennett, Amarjeet Tank, Christopher Edmonds, Phil McEwan
Relationship between hypoglycaemia, body mass index and quality of life among patients with type 1 diabetes: Observations from the DEPICT clinical trial programme. Diabetes, obesity & metabolism 22 (5) (2020)
Hayley Bennett, Amarjeet Tank, Lyndon Marc Evans, Klas Bergenheim, Phil McEwan
Cost-effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the United Kingdom. Diabetes, obesity & metabolism 22 (7) (2020)

Phil McEwan.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Phil McEwan